BioCardia (BCDA) Expected to Announce Quarterly Earnings on Wednesday

BioCardia (NASDAQ:BCDA) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.87) per share and revenue of $0.02 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

BioCardia Stock Down 2.3 %

BCDA opened at $2.60 on Tuesday. BioCardia has a 52-week low of $1.63 and a 52-week high of $6.41. The company has a 50 day moving average of $2.42 and a two-hundred day moving average of $2.41. The company has a market cap of $11.92 million, a P/E ratio of -0.62 and a beta of 1.28.

Insider Buying and Selling

In other BioCardia news, Director Simon H. Stertzer bought 22,753 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were bought at an average cost of $2.30 per share, with a total value of $52,331.90. Following the completion of the acquisition, the director now owns 40,602 shares of the company’s stock, valued at approximately $93,384.60. This trade represents a 127.47 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders have acquired 25,353 shares of company stock worth $58,525. 20.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on BCDA shares. Alliance Global Partners raised BioCardia from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 30th. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of BioCardia in a research note on Wednesday, December 18th.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.